Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2026-03-08 @ 11:20 PM
Study NCT ID:
NCT06322667
Status:
RECRUITING
Last Update Posted:
2025-02-18
First Post:
2024-03-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Sponsor:
Eisai Co., Ltd.
Organization:
Study Overview
Official Title:
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Status:
RECRUITING
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: